The abstract is read at the publisher; the summary is JClub's.
Paediatric MASLD is the leading chronic liver disease in children and adolescents worldwide, rising with obesity and type 2 diabetes, and is linked to early insulin resistance and youth-onset diabetes.
- Why it matters: The field needs endocrine-focused clarity because paediatric MASLD is distinct from adult disease, varies by sex and ancestry, and carries prognostic risks including increased late mortality.
- What they did: The review synthesizes evidence on early hepatic steatosis during insulin resistance, sex/ancestry epidemiology, and puberty as a vulnerability window, and summarizes emerging therapies including glucagon-like peptide-1 receptor agonists and bariatric surgery.
- The result: About 20–25% of affected youth show clinically significant fibrosis on histology, with more severe disease when MASLD coexists with impaired glucose tolerance or type 2 diabetes, supporting targeted screening and paediatric-specific trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.